• Je něco špatně v tomto záznamu ?

Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma

J. Poljakova, J. Hrebackova, M. Dvorakova, M. Moserova, T. Eckschlager, J. Hrabeta, M. Göttlicherova, B. Kopejtkova, E. Frei, R. Kizek, M. Stiborova

. 2011 ; 32 Suppl 1 () : 101-116.

Jazyk angličtina Země Švédsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12024200

OBJECTIVES: Valproic acid (VPA) and trichostatin A (TSA) exert antitumor activity as histone deacetylase inhibitors, whereas ellipticine action is based mainly on DNA intercalation, inhibition of topoisomerase II and formation of cytochrome P450 (CYP)- and peroxidase-mediated covalent DNA adducts. This is the first report on the molecular mechanism of combined treatment of human neuroblastoma UKF-NB-3 and UKF-NB-4 cells with these compounds. METHODS: HPLC with UV detection was employed for the separation and characterization of ellipticine metabolites formed by microsomes and peroxidases. Covalent DNA modifications by ellipticine in neuroblastoma cells and in incubations with microsomes and peroxidases were detected by 32P-postlabeling. Expression of CYP enzymes, peroxidases and cytochrome b5 was examined by Western blot. RESULTS: The cytotoxicity of ellipticine to neuroblastomas was increased by pre-treating these cells with VPA or TSA. A higher sensitivity of cells to ellipticine correlated with an increase in formation of covalent ellipticine-derived DNA adducts in these cells. To evaluate the mechanisms of this finding, we investigated the modulation by VPA and TSA of CYP- and peroxidase-mediated ellipticine-derived DNA adduct formation in vitro. The effects of ellipticine in the presence of VPA and TSA on expression of CYPs and peroxidases relevant for ellipticine activation and levels of cytochrome b5 and P-glycoprotein in neuroblastoma cells were also investigated. Based on these studies, we attribute most of the enhancing effects of VPA and TSA on ellipticine cytotoxicity to enhanced ellipticine-DNA adduct formation caused by an increase in levels of cytochrome b5, CYP3A4 and CYP1A1 in neuroblastoma cells. A lower sensitivity of UKF-NB-4 cells to combined effects of ellipticine with VPA and TSA than of UKF-NB-3 cells is also attributable to high levels of P-glycoprotein expressed in this cell line. CONCLUSION: The results found here warrant further studies and may help in the design of new protocols geared to the treatment of high risk neuroblastomas.

000      
00000naa a2200000 a 4500
001      
bmc12024200
003      
CZ-PrNML
005      
20170411095926.0
007      
ta
008      
120815s2011 sw f 000 0#eng||
009      
AR
035    __
$a (PubMed)22167207
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sw
100    1_
$a Poljakova, Jitka $u Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic.
245    10
$a Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma / $c J. Poljakova, J. Hrebackova, M. Dvorakova, M. Moserova, T. Eckschlager, J. Hrabeta, M. Göttlicherova, B. Kopejtkova, E. Frei, R. Kizek, M. Stiborova
520    9_
$a OBJECTIVES: Valproic acid (VPA) and trichostatin A (TSA) exert antitumor activity as histone deacetylase inhibitors, whereas ellipticine action is based mainly on DNA intercalation, inhibition of topoisomerase II and formation of cytochrome P450 (CYP)- and peroxidase-mediated covalent DNA adducts. This is the first report on the molecular mechanism of combined treatment of human neuroblastoma UKF-NB-3 and UKF-NB-4 cells with these compounds. METHODS: HPLC with UV detection was employed for the separation and characterization of ellipticine metabolites formed by microsomes and peroxidases. Covalent DNA modifications by ellipticine in neuroblastoma cells and in incubations with microsomes and peroxidases were detected by 32P-postlabeling. Expression of CYP enzymes, peroxidases and cytochrome b5 was examined by Western blot. RESULTS: The cytotoxicity of ellipticine to neuroblastomas was increased by pre-treating these cells with VPA or TSA. A higher sensitivity of cells to ellipticine correlated with an increase in formation of covalent ellipticine-derived DNA adducts in these cells. To evaluate the mechanisms of this finding, we investigated the modulation by VPA and TSA of CYP- and peroxidase-mediated ellipticine-derived DNA adduct formation in vitro. The effects of ellipticine in the presence of VPA and TSA on expression of CYPs and peroxidases relevant for ellipticine activation and levels of cytochrome b5 and P-glycoprotein in neuroblastoma cells were also investigated. Based on these studies, we attribute most of the enhancing effects of VPA and TSA on ellipticine cytotoxicity to enhanced ellipticine-DNA adduct formation caused by an increase in levels of cytochrome b5, CYP3A4 and CYP1A1 in neuroblastoma cells. A lower sensitivity of UKF-NB-4 cells to combined effects of ellipticine with VPA and TSA than of UKF-NB-3 cells is also attributable to high levels of P-glycoprotein expressed in this cell line. CONCLUSION: The results found here warrant further studies and may help in the design of new protocols geared to the treatment of high risk neuroblastomas.
650    _2
$a zvířata $7 D000818
650    _2
$a protokoly protinádorové kombinované chemoterapie $x farmakologie $x terapeutické užití $7 D000971
650    _2
$a nádory mozku $x farmakoterapie $x genetika $x patologie $7 D001932
650    _2
$a poškození DNA $7 D004249
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a preklinické hodnocení léčiv $7 D004353
650    _2
$a elipticiny $x aplikace a dávkování $x farmakologie $7 D004611
650    _2
$a inhibitory histondeacetylas $x aplikace a dávkování $x farmakologie $7 D056572
650    _2
$a lidé $7 D006801
650    _2
$a kyseliny hydroxamové $x aplikace a dávkování $x farmakologie $7 D006877
650    _2
$a jaterní mikrozomy $x účinky léků $x metabolismus $7 D008862
650    _2
$a biologické modely $7 D008954
650    _2
$a neuroblastom $x farmakoterapie $x genetika $x patologie $7 D009447
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a výsledek terapie $7 D016896
650    _2
$a nádorové buňky kultivované $7 D014407
650    _2
$a kyselina valproová $x aplikace a dávkování $x farmakologie $7 D014635
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hrebackova, Jana
700    1_
$a Dvorakova, Marketa
700    1_
$a Moserova, Michaela
700    1_
$a Eckschlager, Tomas
700    1_
$a Hrabeta, Jan
700    1_
$a Göttlicherova, Marketa
700    1_
$a Kopejtkova, Barbora
700    1_
$a Frei, Eva
700    1_
$a Kizek, Rene
700    1_
$a Stiborova, Marie
773    0_
$w MED00168352 $t Neuro endocrinology letters $x 0172-780X $g Roč. 32 Suppl 1(2011), s. 101-116
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22167207 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120815 $b ABA008
991    __
$a 20170411100225 $b ABA008
999    __
$a ok $b bmc $g 946348 $s 781528
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 32 Suppl 1 $d 101-116 $i 0172-780X $m Neuro-endocrinology letters $n Neuro-endocrinol. lett. $x MED00168352
LZP    __
$a Pubmed-20120815/12/02

Najít záznam

Citační ukazatele

Možnosti archivace